Table 2 Clinical assessments and bone turnover in AS patients still using their first TNF-α blocking agent
Assessment | Baseline | 3 months | P* | 6 months | P* | 12 months | P* | 24 months | P* | 36 months | P* |
|---|---|---|---|---|---|---|---|---|---|---|---|
BASDAI (range 0 to 10) | 6.0 ± 1.7 | 2.5 ± 1.6 | 0.000 | 2.3 ± 1.7 | 0.000 | 2.7 ± 2.1 | 0.000 | 2.5 ± 1.8 | 0.000 | 2.6 ± 1.7 | 0.000 |
ASDASCRP | 3.9 ± 0.8 | 1.7 ± 0.7 | 0.000 | 1.6 ± 0.7 | 0.000 | 1.9 ± 0.9 | 0.000 | 1.9 ± 0.8 | 0.000 | 1.8 ± 0.8 | 0.000 |
Physician's GDA (range 0 to 10) | 5 (1 to 9) | 2 (0 to 5) | 0.000 | 1 (0 to 8) | 0.000 | 1 (0 to 7) | 0.000 | 0 (0 to 6) | 0.000 | 0 (0 to 3) | 0.000 |
Patient's GDA (range 0 to 10) | 6 (1 to 10) | 2 (0 to 8) | 0.000 | 2 (0 to 8) | 0.000 | 2 (0 to 10) | 0.000 | 2 (0 to 8) | 0.000 | 2 (0 to 7) | 0.000 |
ESR (mm/h) | 22 (2 to 90) | 5 (2 to 35) | 0.000 | 6 (2 to 36) | 0.000 | 7 (2 to 52) | 0.000 | 9 (2 to 46) | 0.000 | 8 (2 to 48) | 0.000 |
CRP (mg/l) | 16 (2 to 99) | 3 (2 to 20) | 0.000 | 3 (2 to 21) | 0.000 | 3 (2 to 38) | 0.000 | 3 (2 to 61) | 0.000 | 3 (2 to 57) | 0.000 |
BALP Z-score | 0.19 (-1.64 to 3.91) | 0.94 (-1.49 to 5.12) | 0.000 | 0.48 (-1.26 to 4.37) | 0.000 | 0.87 (-1.34 to 6.69) | 0.000 | 0.58 (-1.46 to 6.11) | 0.000 | 1.09 (-1.33 to 9.27) | 0.000 |
PINP Z-score | 0.36 (-1.75 to 3.63) | 0.50 (-1.54 to 4.55) | 0.047 | 0.54 (-1.47 to 5.33) | 0.054 | 0.28 (-1.52 to 5.53) | 0.102 | 0.57 (-1.51 to 7.17) | 0.013 | 0.28 (-1.45 to 2.43) | 0.247 |
sCTX Z-score | -0.02 (-2.58 to 4.01) | -0.74 (-2.53 to 2.29) | 0.000 | -0.55 (-2.25 to 3.99) | 0.002 | -0.45 (-2.23 to 3.11) | 0.011 | -0.34 (-2.15 to 4.31) | 0.119 | -0.70 (-2.50 to 4.15) | 0.019 |
LS BMD Z-score | -0.36 ± 1.56 |  |  |  |  | 0.04 ± 1.42 | 0.000 | 0.20 ± 1.39 | 0.000 | 0.48 ± 1.61 | 0.000 |
Hip BMD Z-score | -0.40 ± 1.06 |  |  |  |  | -0.32 ± 0.91 | 0.000 | -0.24 ± 1.01 | 0.000 | -0.16 ± 1.03 | 0.000 |